Hydroxymethylbilane synthase (aka porphobilinogen deaminase): A novel metabolic tumor suppressor gene in hepatocellular carcinoma

Affiliations

¹ Program of Hepatology, CIMA, University of Navarra, Pamplona, Spain; CIBERehd, ISCIII, Madrid, Spain; IdiSNA, Pamplona, Spain. Electronic address: afontanellas@unav.es.
² Program of Hepatology, CIMA, University of Navarra, Pamplona, Spain; CIBERehd, ISCIII, Madrid, Spain; IdiSNA, Pamplona, Spain. Electronic address: maavila@unav.es.

Editorial

Antonio Fontanellas et al. J Hepatol. 2022 Oct.

. 2022 Oct;77(4):912-914.

doi: 10.1016/j.jhep.2022.06.023. Epub 2022 Jul 5.

¹ Program of Hepatology, CIMA, University of Navarra, Pamplona, Spain; CIBERehd, ISCIII, Madrid, Spain; IdiSNA, Pamplona, Spain. Electronic address: afontanellas@unav.es.
² Program of Hepatology, CIMA, University of Navarra, Pamplona, Spain; CIBERehd, ISCIII, Madrid, Spain; IdiSNA, Pamplona, Spain. Electronic address: maavila@unav.es.

No abstract available

Conflict of interest statement

Conflict of interest The authors declare no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
Molina L, Zhu J, Trépo E, Bayard Q, Amaddeo G; GENTHEP Consortium; Blanc JF, Calderaro J, Ma X, Zucman-Rossi J, Letouzé E. Molina L, et al. J Hepatol. 2022 Oct;77(4):1038-1046. doi: 10.1016/j.jhep.2022.05.018. Epub 2022 May 27. J Hepatol. 2022. PMID: 35636578 Free PMC article.